Xenetic Biosciences- Warrants (19/07/2024) P/E Ratio

Xenetic Biosciences- Warrants (19/07/2024) (XBIOW) currently reports a P/E ratio of -2.01. That is below the Healthcare sector average of 27.28. Use the charts on this page to explore Xenetic Biosciences- Warrants (19/07/2024)'s P/E ratio history and peer comparisons.

Xenetic Biosciences- Warrants (19/07/2024)'s P/E ratio of -2.01 is lower than the Healthcare sector average of 27.28. That is roughly 107.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Xenetic Biosciences- Warrants (19/07/2024)'s market price to a fundamental measure such as earnings, sales, or book value. At -2.01, XBIOW can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -2.01, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.28. From there, open related valuation or income-statement pages for Xenetic Biosciences- Warrants (19/07/2024), and consider following XBIOW for alerts when major investors trade the stock.

Xenetic Biosciences- Warrants (19/07/2024) is classified in the Healthcare sector. On P/E ratio, it currently shows -2.01 versus a sector average near 27.28. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XBIOW with unrelated industries.